Ladenburg Thalmann Financial Services’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-100
| Closed | – | – | 5620 |
|
|
2018
Q2 | $0 | Hold |
100
| – | – | ﹤0.01% | 5249 |
|
|
2018
Q1 | $0 | Hold |
100
| – | – | ﹤0.01% | 5388 |
|
|
2017
Q4 | $0 | Buy |
100
+90
| +900% | +$147 | ﹤0.01% | 5302 |
|
|
2017
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 5223 |
|
|
2017
Q2 | $0 | Sell |
10
-500
| -98% | -$1.5K | ﹤0.01% | 5170 |
|
|
2017
Q1 | $2K | Buy |
510
+500
| +5,000% | +$1.97K | ﹤0.01% | 4658 |
|
|
2016
Q4 | $0 | Sell |
10
-25
| -71% | -$59 | ﹤0.01% | 5141 |
|
|
2016
Q3 | $0 | Sell |
35
-50
| -59% | -$189 | ﹤0.01% | 5095 |
|
|
2016
Q2 | $0 | Buy |
85
+50
| +143% | +$226 | ﹤0.01% | 5077 |
|
|
2016
Q1 | $0 | Hold |
35
| – | – | ﹤0.01% | 5064 |
|
|
2015
Q4 | $0 | Hold |
35
| – | – | ﹤0.01% | 5016 |
|
|
2015
Q3 | $1K | Sell |
35
-43
| -55% | -$1.47K | ﹤0.01% | 4575 |
|
|
2015
Q2 | $4K | Hold |
78
| – | – | ﹤0.01% | 4203 |
|
|
2015
Q1 | $6K | Sell |
78
-108
| -58% | -$6.7K | ﹤0.01% | 3940 |
|
|
2014
Q4 | $11K | Buy |
186
+161
| +644% | +$8.09K | ﹤0.01% | 3402 |
|
|
2014
Q3 | $1K | Sell |
25
-15
| -38% | -$806 | ﹤0.01% | 3901 |
|
|
2014
Q2 | $2K | Hold |
40
| – | – | ﹤0.01% | 3728 |
|
|
2014
Q1 | $3K | Buy |
40
+15
| +60% | +$1.01K | ﹤0.01% | 3479 |
|
|
2013
Q4 | $1K | Hold |
25
| – | – | ﹤0.01% | 3712 |
|
|
2013
Q3 | $2K | Hold |
25
| – | – | ﹤0.01% | 3522 |
|
|
2013
Q2 | $1K | Buy |
+25
| New | +$1.54K | ﹤0.01% | 3594 |
|
Ladenburg Thalmann Financial Services's OREX Position: Q3 2018 in Review
Ladenburg Thalmann Financial Services sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2018, closing a stake of 100 shares.
Ladenburg Thalmann Financial Services first reported a position in OREX in Q2 2013 and held it in 21 quarters. The position peaked at $11K in Q4 2014. 1 fund tracked by Wall St. Rank holds OREX as of Q3 2018.
- Ladenburg Thalmann Financial Services reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
- Ladenburg Thalmann Financial Services sold 100 Orexigen Therapeutics, Inc. shares in Q3 2018.
- Ladenburg Thalmann Financial Services first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 21 quarters.
- Ladenburg Thalmann Financial Services's Orexigen Therapeutics, Inc. position peaked at $11K in Q4 2014.
- 1 fund tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2018.
Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2018, filed 14 Nov 2018.